Isis Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs to treat various therapeutic areas, including inflammatory, metabolic, and cardiovascular diseases, as well as cancer. The company operates through two segments, Drug Discovery and Development, and Ibis. The Drug Discovery and Development segment develops antisense inhibitors through its proprietary technology. The company markets its antisense drug, Vitravene, for the treatment of cytomegalovirus and retinitis in AIDS patients in the United States and Europe. It also develops new formulations of antisense drugs, such as oral, topical cream, subcutaneous, intravitreal, aerosol, and enema. The company's drugs under development include Alicaforsen for Ulcerative Colitis in Phase II clinical trial and ISIS 113715 for diabetes in Phase II clinical trial. In addition, it develops second-generation inhibitors, such as apoB-100 for the lowering of cholesterol and ISIS 301012, a Phase I study of an oral capsule formulation. The Ibis segment offers Triangulation Identification for Genetic Evaluation of Risks (TIGER) technology, a biosensor system, for identification of infectious diseases. TIGER biosensor system identifies various bacteria and viruses in both environmental and human clinical samples and used for epidemiological surveillance, biological products screening, and microbial forensics applications. The company has strategic alliance and collaboration agreements with Novartis Ophthalmics AG; Ercole Biotech, Inc.; Alnylam Pharmaceuticals, Inc.; OncoGenex Technologies, Inc.; Santaris Pharma A/S; Eli Lilly and Company; Antisense Therapeutics, Ltd.; and Sarissa, Inc. Isis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, California.
Premarket, intraday, nightly, and weekend updates, which include stock picks with full instructions, market direction (short, intermediate, long term), precious metal, commodity, and currency analysis.
Provide you stock picks (breakouts) and market direction to help you become
more profitable.
Voice over chart updates sent to you by e-mail. These updates contain stock picks and market status for a number of different portfolios, which Trending123 is recommending and following.
Instantaneous e-mail alerts during the trading day when targets have been hit or the status of a position or the market warrants a move. Stock Recommendations for swing traders, day traders, and long term investors.
Receive instant emails to your computer, organizer, cell phone of breakouts on stocks.....Learn More
Stock quotes, stock research, stock scan and picks and free stock chart pattern recognition from Trending 123.com for smart stock market investing. We feature daily stock market email alerts including equities, indices, and currencies, identified through technical analysis trends patterns and waves. Sign up today!
Financial Market Data powered by Quotemedia.com. All rights reserved. Terms and conditions.
NYSE/AMEX data delayed 20 minutes. NASDAQ/other data delayed 15 minutes unless indicated.
